|Bid||2.3000 x 4000|
|Ask||2.3200 x 45900|
|Day's Range||2.3000 - 2.4400|
|52 Week Range||1.8200 - 6.0900|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.94|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, and PlushCare, a virtual health platform that enables patients to book a virtual doctor's appointment to get treatment, today announced that TherapeuticsMD's women's health products can be prescribed to patients via the PlushCare platform.
TXMD's women's health products now available to be prescribed through virtual health platform, PlushCare
TXMD at 38th Annual J.P. Morgan Healthcare Conference in San Francisco; CEO Robert Finizio to present on January 15th @ 9:30 am PST
TXMD amends terms of financing facility; $50 million loan tranche no longer tied to ANNOVERA's designation as a new category of birth control by FDA
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly...
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2019 Healthcare Conference in New York City. TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. To learn more about TherapeuticsMD, please visit www.therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 31.58% and 200.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019, after the closing of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 4:30 p.m. ET on such date to discuss the Company’s financial results and provide a business update. A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at www.therapeuticsmd.com.
Knight Therapeutics Inc. (GUD.TO) (“Knight”) and TherapeuticsMD, Inc. (TXMD) (“TherapeuticsMD”) announced today that Knight's New Drug Submission (NDS) for Joyesta™ has been accepted for review by Health Canada. Joyesta, licensed from TherapeuticsMD, is an applicator-free estradiol softgel vaginal capsule for the treatment of postmenopausal symptoms of vulvar and vaginal atrophy due to estrogen deficiency. Joyesta is marketed as IMVEXXY® (estradiol vaginal inserts) by TherapeuticsMD in the U.S., for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
TherapeuticsMD (TXMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TherapeuticsMD, Inc. (TXMD) today announced the closing of its underwritten public offering of 29,900,000 shares of its common stock at a price to the public of $2.75 per share, inclusive of the underwriters’ option to purchase additional shares of common stock, which option was exercised in full. TherapeuticsMD received net proceeds from the offering of approximately $77.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD.
TherapeuticsMD, Inc. (TXMD) today announced the pricing of its underwritten public offering of 26,000,000 shares of its common stock at a price to the public of $2.75 per share. TherapeuticsMD has also granted to the underwriters of the offering a 30-day option to purchase up to an additional 3,900,000 shares of common stock at the public offering price, less the underwriting discount. The gross proceeds to TherapeuticsMD from the offering are expected to be $71.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by TherapeuticsMD, assuming no exercise of the underwriters’ option to purchase additional shares of common stock.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) AVITA ...
TherapeuticsMD, Inc. (TXMD) today announced the launch of an underwritten public offering of 22,000,000 shares of its common stock. TherapeuticsMD also expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 3,300,000 shares of common stock at the public offering price, less the underwriting discount. All of the shares in the offering are to be sold by TherapeuticsMD.
TherapeuticsMD, Inc. (TXMD) (the “Company”) today announced its estimates of the financial results for the third quarter ended September 30, 2019. For the three months ended September 30, 2019, the Company estimates that its consolidated net revenue from its prescription vitamin business will range from approximately $2.50 million to $2.60 million, compared to consolidated net revenue from its prescription vitamin business of approximately $2.80 million for the three months ended June 30, 2019. For the three months ended September 30, 2019, the Company estimates that its consolidated net revenue from sales of its U.S. Food and Drug Administration approved products IMVEXXY®, BIJUVA®, and ANNOVERA® will range from approximately $5.32 million to $5.70 million, compared to consolidated net revenue from sales of IMVEXXY and BIJUVA of approximately $3.3 million for the three months ended June 30, 2019.
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the presentation of ANNOVERA™ findings at the annual meeting of the American Society for Reproductive Medicine being held in Philadelphia, PA on October 12-16, 2019.
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that Jennifer Wilson, Vice President of Business Development, has been named a Finalist in the Female Executive of the Year – Business Products category in the 16th annual Stevie® Awards for Women in Business. The Stevie Awards for Women in Business honor women executives, entrepreneurs, employees and the companies they run – worldwide. The Stevie Awards have been hailed as the world’s premier business awards.